rBS-WC霍乱疫苗的动物免疫方案及免疫持久性

用小鼠、家兔观察了rBS-WS疫苗免疫的部分方案的效果。rBS与WC单独使用的免疫效果不如组合使用的效果好;小鼠或家兔的免疫间隔作适当缩短对免疫保护影响不大;小鼠一次大剂量口服疫苗后亦可获得良好保护。家兔肌肉注射免疫条件下rBS-WC与吸附霍乱类毒素菌苗(上海苗)及吸附霍乱菌苗(武汉苗)进行比较,武汉苗无抗CT反应,对CT攻击无保护,对Eltor(小川)攻击保护效果较差,上海苗则抗CT反应较低。家兔口服rBS-WC半年后,抗CT及杀弧菌抗体维持较高水平,显示其动物免疫的持久性。     

O1或O139霍乱疫苗对异群霍乱缺乏交叉保护

O1和O139霍乱弧菌是引起急性腹泻的病原微生物,用这两群菌的灭活全菌体与重组霍乱毒素B亚单位构建的亚单位／菌体型疫苗免疫队CA小鼠,对本群菌的攻击可提供良好免疫保护,而对异群霍乱菌则缺乏交叉保护作用。     

植物口服疫苗的动物和临床实验*

利用转基因植物生产亚单位疫苗用于口服主动免疫具有安全、廉价和方便等优点。植物可以正确地表达细菌和病毒抗原基因,对动物及人类的临床实验研究表明：食用表达某种抗原的转基因植物可在实验动物或人群体内激起系统免疫和粘膜免疫,产生相应的特异性抗体,这些结果表明了植物口服疫苗的可行性。此外,在治疗自身免疫疾病以及癌症等方面,植物口服疫苗也具有值得关注的作用。     

以霍乱毒素B亚基为佐剂的SARS病毒核酸疫苗的构建

由于冠状病毒主要通过粘膜系统侵人细胞,因此有效的粘膜免疫效应对于SARS的免疫预防具有重要作用。通过将SARS冠状病毒免疫保护相关的核衣壳蛋白和辐条蛋白与霍乱毒素B亚基基因融合,并克隆至真核基因表达载体,所构建的DNA候选疫苗在细胞内可表达霍乱毒素B亚基与SARS抗原的融合蛋白,从而可用于评价是否可有效产生粘膜免疫。     

rBS-WC(O139)霍乱疫苗的小鼠免疫试验

1992年起在印度和孟加拉国相继发生的O139霍乱,目前已迅速传播到其周边国家,对我国亦已构成严重威胁。当前全世界预防霍乱的工作更加复杂,除了要针对O1群霍乱弧菌研制保护期长、保护效率高的疫苗外,还要对这一新发现的时隐时现的烈性腹泻病原菌快速作出反应,及时分析其保护性抗原,构建有效疫苗,以控制疫情发展。 O139霍乱弧菌与O1群霍乱弧菌有很大不同,特别在菌体抗原方面存在显著差异。O1群菌感染的患者康复后对同群菌的冉感染有免疫保护作用,而对O139群菌的感染则无此保护作     

烟草生产霍乱毒素B亚单位疫苗的免疫分析

用纯化的ＣＴＢ后腿肌肉注射免疫小鼠,每次１２．５μｇ,每隔１４天加强一次,共注射三次,末次免疫后两周收集血清,免疫小鼠诱导产生了特异性抗ＣＴＢ抗体。在ＣＨＯ细胞中,免疫小鼠血清能够中和ＣＴ的细胞病变效应;小鼠肠结扎实验表明,抗ＣＴＢ血清能够抑制ＣＴ结合细胞表面受体ＧＭ１神经节苷脂。这表明转基因烟草产ＣＴＢ在小鼠中能够产生抗细菌毒素的保护免疫力。     

O1群霍乱Ogawa血清型结合疫苗免疫学效果研究

霍乱是经粪口传播的烈性传染病,相应的疫苗研究已逾百年,但目前还没有理想的疫苗。实验中以霍乱O1群小川血清型的脂多糖为目标抗原,用不同方法制备了其四种霍乱结合疫苗,通过小鼠模型验证了各结合物的免疫学效果。结果显示,不同结合物免疫学效果不一,其中增大多糖分子量后制备的结合物免疫效果较好,氨还原法制备的结合物多针免疫后也可诱导特异性抗体产生,而且具有针对小川和稻叶两种血清型的杀弧菌活性。     

冻干口服霍乱rBS—WC菌苗安全及保护效果评价的小鼠模型探讨

本文仿照人口服免疫程序用小鼠为模型对冻干口服霍乱ｒＢＳ－ＷＣ菌苗制品进行了安全及保护率评价。给ＫＭ小鼠口服三种不同剂量的ｒＢＳ－ＷＣ菌苗后,无发病,无体重减轻,无死亡现象,表明该菌苗安全,无毒副作用。免疫组与安慰剂组小鼠用肠结扎攻毒试验评价保护效果,两组小鼠用吴江－２及滨－４３活菌攻击后,免疫组显示良好保护作用（Ｐ＜０．０５）。此法可以用于口服型ｒＢＳ－ＷＣ菌苗的评价,但也存在需要动物数较多,个体间差异较大,手术较麻烦的问题。     

霍乱O139血清群多糖结合疫苗的生物合成研究

目的:霍乱是由霍乱弧菌引起的一种烈性传染病,其防治已成为一个全球性的公共卫生问题。其中1992年出现的O139血清群是除O1外另一种病原体,发病数日益增多。因此,有必要寻找一种安全有效适用于各种人群的疫苗。方法:敲除霍乱弧菌O139血清群93-3株脂多糖合成途径中O抗原连接酶基因waa L,在周间质产生游离的多糖,之后转入包含来自脑膜炎奈瑟球菌的糖基转移酶和霍乱毒素B亚单位(CTB)编码序列的共表达载体,经IPTG诱导后制备全菌蛋白样品,利用抗His抗体检测糖蛋白的表达,利用Ni柱和离子交换柱对糖蛋白进行纯化,并对其进行糖定量和蛋白定量。结果:以未糖基化、相对分子质量约为14×103的底物蛋白CTB为对照,当共表达CTB和糖基转移酶Pgl L时,通过Western印迹可检测到相对分子质量约为20×103的糖基化蛋白,经Ni柱及阳离子交换柱纯化,得到纯度较高的O139群霍乱O抗原多糖结合蛋白,其纯度约为84.2%,并计算得其糖-蛋白比为0.103∶1。结论:通过生物法合成了一种霍乱O139血清群的多糖结合疫苗,为后续进行动物评价打下了基础。     

重组霍乱毒素B亚基与恶性疟原虫多抗原表位融合蛋白对恒河猴的免疫保护作用研究

使用重组霍乱毒素B亚基（CTB）与恶性疟原虫抗原表位融合蛋白（AWTE）免疫恒河猴,研究其免疫应答并观察对食蟹疟原虫攻击的保护作用。结果表明：在0,14,28天分别通过鼻腔和肌肉注射免疫恒河猴,第3次免疫后2周,抗CTB抗体平均滴度可达1∶512（鼻腔免疫）和1∶10000（肌肉免疫）;肌肉免疫后抗疟原虫抗体滴度也显著高于鼻腔免疫组。用125×10⁸个食蟹疟子孢子攻击,对照组5只恒河猴在攻击后10～14d全部感染,其中1只在攻击后21d死亡,另4只重度感染,感染持续30d以上。鼻腔免疫组的5只动物均在攻击20d后出现原虫,其中3只轻度感染,感染持续4d后即恢复,其余2只感染持续36d以上。肌肉注射组3只未受感染,其余2只在攻击后19d后轻度感染,感染4d后即完全恢复。以上结果表明,使用霍乱毒素B亚基为载体蛋白构建的重组疟疾疫苗具有良好的免疫原性,对食蟹疟攻击具有良好的交叉免疫保护作用。     

O139型霍乱菌苗人群副反应观察报告

在广西田阳县中学生中,分６组共６９７人进行了Ｏ１３９型霍乱菌苗与Ｏ１群霍乱菌苗的双盲、有对照的人体反应现场观察。结果表明,不加铝佐剂的Ｏ１３９型霍乱菌苗及Ｏ１群霍乱菌苗,不论是低剂量组（两剂全程接种４５亿菌体）抑或常剂量组（全程接种９０亿）接种人群均可产生１０～２５％的体温呈轻度升高的弱反应,并且同种菌苗的两剂量组的反应率无显著差异;第一剂接种的反应率（１９～２５％）较第二剂接种的（１０～１５％）高,Ｐ＜０．０５;接种局部反应轻微,只有个别受试者出现直径小于１５ｍｍ的硬结;加佐剂的Ｏ１群吸附霍乱菌苗的反应较其它组强。结果证实,甲醛灭活的Ｏ１３９型霍乱菌苗和Ｏ１群霍乱菌苗是安全的,接种人体对之具有良好的耐受性     

霍乱O139型菌苗的试制

对来自孟加拉、泰国、印度、中国四地区Ｏ１３９型霍乱菌株进行了毒力、免疫原性、免疫力与相互交叉保护力试验,结果显示不同地区分离的Ｏ１３９型霍乱弧菌其所试特性相互间无差异。用中国（９３－３）株试制的菌体菌苗,其抗原性、毒性、免疫力安全性等经检定符合霍乱菌苗规程要求。鉴于Ｏ１３９型霍乱弧菌存在荚膜的特性,而现有的几种荚膜多糖菌苗都显示有明显的保护作用,因而,使用Ｏ１３９型菌苗有可能在一定程度上达到控制Ｏ１３９型霍乱流行的目的。     

Immunogenicity of a Killed Bivalent (O1 and O139) Whole Cell Oral Cholera Vaccine,Shanchol, in Haiti

Background

Studies of the immunogenicity of the killed bivalent whole cell oral cholera vaccine, Shanchol, have been performed in historically cholera-endemic areas of Asia. There is a need to assess the immunogenicity of the vaccine in Haiti and other populations without historical exposure to Vibrio cholerae.

Methodology/Principal Findings

We measured immune responses after administration of Shanchol, in 25 adults, 51 older children (6–17 years), and 47 younger children (1–5 years) in Haiti, where cholera was introduced in 2010. A≥4-fold increase in vibriocidal antibody titer against V. cholerae O1 Ogawa was observed in 91% of adults, 74% of older children, and 73% of younger children after two doses of Shanchol; similar responses were observed against the Inaba serotype. A≥2-fold increase in serum O-antigen specific polysaccharide IgA antibody levels against V. cholerae O1 Ogawa was observed in 59% of adults, 45% of older children, and 61% of younger children; similar responses were observed against the Inaba serotype. We compared immune responses in Haitian individuals with age- and blood group-matched individuals from Bangladesh, a historically cholera-endemic area. The geometric mean vibriocidal titers after the first dose of vaccine were lower in Haitian than in Bangladeshi vaccinees. However, the mean vibriocidal titers did not differ between the two groups after the second dose of the vaccine.

Conclusions/Significance

A killed bivalent whole cell oral cholera vaccine, Shanchol, is highly immunogenic in Haitian adults and children. A two-dose regimen may be important in Haiti, and other populations lacking previous repeated exposures to V. cholerae.     

O139霍乱灭活全菌体菌苗免疫后人群抗体水平测定

Ｏ１３９霍乱弧菌经甲醛灭活制备而成的全菌体菌苗在广西田阳县进行临床考核。每组５０名中学生经肌肉途径接种４５亿菌和９０亿菌两种剂量,一个月后８０％接种者血清中杀弧菌抗体升高,最高可达１∶１６０,免疫后３个月开始缓慢下降,但仍有６８－７２％接种者抗体效价在１∶２０以上。高剂量组半数接种者的杀弧菌抗体可维持存在６个月。血清中凝集抗体升高明显,但３个月后下降也明显。与对照组Ｏ１菌苗相比,两种抗体水平升高与下降趋势一致。采用ＥＬＩＳＡ法测定抗毒抗体,Ｏ１３９菌苗组与Ｏ１菌苗组结果相似,均有一定上升。上述结果提示Ｏ１３９霍乱灭活菌苗可作为短效应急菌苗使用     

戈登链球菌的生物学特性及在黏膜疫苗的应用

戈登氏链球菌是一种非致病性革兰氏阳性黏膜共生菌,参与组成人类口腔正常菌群.它具有特殊的生物学特性,非常适合作为黏膜疫苗的载体.了解戈登氏链球菌的生物学特性,常用表达体系及该菌在黏膜疫苗的应用情况,将为其黏膜疫苗的进一步研制提供重要参考.     

戈登链球菌的生物学特性及在黏膜疫苗的应用

戈登氏链球菌是一种非致病性革兰氏阳性黏膜共生菌, 参与组成人类口腔正常菌群。它具有特殊的生物学特性, 非常适合作为黏膜疫苗的载体。了解戈登氏链球菌的生物学特性, 常用表达体系及该菌在黏膜疫苗的应用情况, 将为其黏膜疫苗的进一步研制提供重要参考。     

Immunogenicity of Vibrio cholerae O1 Fimbriae in Animal and Human Cholera

Parenteral immunization with either formalin-fixed whole cells of the fimbriate Bgd17 strain or purified fimbriae protected against Vibrio cholerae O1 infection in rabbits, independent of biotype and serotype. Parenteral immunization of adult rabbits with purified fimbriae prior to V. cholerae O1 challenge resulted in a reduction of 2 to 3 orders of magnitude in the number of bacteria recovered from the small intestines of immunized rabbits in comparison to non-immunized controls. IgG and IgA antibodies against fimbrillin of V. cholerae O1 were detected in the convalescent sera of patients with cholera; however, little fimbrial antigen was detected in the commercially available cholera vaccines when examined by polyclonal and monoclonal antibodies against fimbriae. These data suggest that fimbrial hemagglutinin is a major adhesin of V. cholerae O1 and that parenteral immunization with fimbriae generates a specific immune response in the gut that may serve as one means of mitigating subsequent V. cholerae O1 gut infection.     

Seasonal Cholera Caused by Vibrio cholerae Serogroups O1 and O139 in the Coastal Aquatic Environment of Bangladesh

Since Vibrio cholerae O139 first appeared in 1992, both O1 El Tor and O139 have been recognized as the epidemic serogroups, although their geographic distribution, endemicity, and reservoir are not fully understood. To address this lack of information, a study of the epidemiology and ecology of V. cholerae O1 and O139 was carried out in two coastal areas, Bakerganj and Mathbaria, Bangladesh, where cholera occurs seasonally. The results of a biweekly clinical study (January 2004 to May 2005), employing culture methods, and of an ecological study (monthly in Bakerganj and biweekly in Mathbaria from March 2004 to May 2005), employing direct and enrichment culture, colony blot hybridization, and direct fluorescent-antibody methods, showed that cholera is endemic in both Bakerganj and Mathbaria and that V. cholerae O1, O139, and non-O1/non-O139 are autochthonous to the aquatic environment. Although V. cholerae O1 and O139 were isolated from both areas, most noteworthy was the isolation of V. cholerae O139 in March, July, and September 2004 in Mathbaria, where seasonal cholera was clinically linked only to V. cholerae O1. In Mathbaria, V. cholerae O139 emerged as the sole cause of a significant outbreak of cholera in March 2005. V. cholerae O1 reemerged clinically in April 2005 and established dominance over V. cholerae O139, continuing to cause cholera in Mathbaria. In conclusion, the epidemic potential and coastal aquatic reservoir for V. cholerae O139 have been demonstrated. Based on the results of this study, the coastal ecosystem of the Bay of Bengal is concluded to be a significant reservoir for the epidemic serogroups of V. cholerae.     

乙型脑炎减毒活疫苗(SA_(14)-14-2)在豚鼠体内保护作用的免疫机制的研究

本实验将乙脑减毒活疫苗ＳＡ_（１４）－１４－２株以不同疫苗病毒量（３．８７ＰＦＵ／ｍｌ和５．８７ＰＦＵ／ｍｌ）分别一次免疫豚鼠,观察其对强毒攻击后抑制毒血症和抗体形成的能力。结果显示疫苗（５．８７ＰＦＵ／ｍｌ）免疫组豚鼠攻击前虽然中和抗体阴性或很低,但经攻击感染后不同时间内均未出现病毒血症,对照组豚鼠则于第２,３,４天全部出现病毒血症。表明一次活疫苗免疫后能有效地抑制病毒血症的产生。免疫后３０天虽然免疫组的豚鼠中和抗体很低,但攻击感染后抗体迅速增长。第四天的抗体滴度为１：８～３２,第５天达１：１２８～２５６,第１４天抗体高达１：５１２～１０２４;而对照组抗体则上升很慢,第７天才出现低水平抗体（１：４）。血凝抑制抗体增长的动态与中和抗体近似。表明活疫苗免疫后虽然中和抗体水平不高,但一经感染可迅速产生高滴度抗体达到保护作用。